Marshall Wace’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Marshall Wace’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-128,007	Closed	-$218K	–	1931
2018 Q3	$218K	Buy	+128,007	New	+$229K	﹤0.01%	1059
2015 Q4	–	Sell	-54,278	Closed	-$288K	–	1202
2015 Q3	$288K	Buy	54,278 +30,032	+124%	+$232K	﹤0.01%	808
2015 Q2	$201K	Buy	+24,246	New	+$118K	﹤0.01%	820

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

OCM

Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace's SGYP Position: Q4 2018 in Review

Marshall Wace sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2018, closing a stake of 128,007 shares — an estimated $218K sold.

Marshall Wace first reported a position in SGYP in Q2 2015 and held it in 3 quarters. The position peaked at $288K in Q3 2015. 89 funds tracked by Wall St. Rank hold SGYP as of Q4 2018.

Marshall Wace reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2018 after selling out during the quarter.
Marshall Wace sold 128,007 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2018, an estimated $218K.
Marshall Wace first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2015 and held it in 3 quarters.
Marshall Wace's Synergy Pharmaceuticals, Inc Common Stock position peaked at $288K in Q3 2015.
89 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2018.

Based on Marshall Wace's 13F filing for Q4 2018, filed 14 Feb 2019.